A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.

PLoS One · 2011 · PMC3237436 · PMID 22194822

Europe PMC DOI

hedged sentence

0.0994

closest p · 2.0× alpha

0.0994

boldest claim

The sentences

only marginally significantp = 0.0994so close (0.05 < p ≤ 0.1)

The same GP score predicted OS after diagnosis on the validation dataset as a dichotomous variable (p = 0.0182), but was only marginally significant as a continuous variable (p = 0.0994).

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.